We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Array Technologies Inc | NASDAQ:ARRY | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.12 | 0.97% | 12.46 | 12.33 | 13.00 | 13.18 | 12.285 | 12.38 | 6,324,975 | 00:56:47 |
From May 2019 to May 2024
By Razak Musah Baba
LONDON--AstraZeneca PLC's (AZN.LN) selumetinib drug has been approved by the U.S. Food and Drug Administration for treatment of Uveal melanoma, a rare eye disease.
The biopharmaceutical firm said Friday that the FDA has granted Orphan Drug Designation for the MEK inhibitor selumetinib, for the treatment of uveal melanoma, a rare disease in which cancer cells form in the tissues of the eye.
The Orphan Drug Designation program provides orphan status to drugs and biologics, which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S.
AstraZeneca acquired exclusive worldwide rights to selumetinib from Array BioPharma Inc in 2003.
Write to Razak Musah Baba at razak.baba@wsj.com; Twitter: @Raztweet
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Array Technologies Chart |
1 Month Array Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
